AbbVie Inc. (NYSE: ABBV) reported positive results from its Phase 2 ELATE trial evaluating onabotulinumtoxinA (Botox) for treating upper limb ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE